Albert Schweitzer Ziekenhuis — Clinical Trial Site

122 Registered trials

52 Currently recruiting

Organisation

Albert Schweitzer Ziekenhuis

Location

Dordrecht, Netherlands

Identifier

ORG-100042264

Address

Langeweg 336, 3331 LZ, Netherlands

Departments

-
#2153: Hematology
#2201: oncology
#2906:Internal Medicine
031006: Oncology
5002:Internal medicine
Afd. Interne geneeskunde
Afdeling Interne geneeskunde, Trials & Research
Afdeling Interne geneeskunde
ASZ Dordrecht dept. Internal medicine
Cardiologie
Cardiology
Clinical Pharmacy
Department Internal Medicine
Department of Hematology
Department of Internal Medicine
Department of Neurology
Department of Surgical Oncology
Diabatescentrum voor volwassenen (Diabetes center for adults)
Endocrinologie
Gastroenterology
Gynaecology
Hematologie
Hematology
Intensive Care
Internal Medicine
Internal Medicine - Hematology
Internal medicine / Hematology
Internal Medicine / Oncology
Internal Medicine Department
Internal Medicine, Hemato-Oncology
Internal medicine, hematology
Internal Medicine, Vascular Medicine
Internal medicine/haematology
Internal Oncology
Interne geneeskunde
Interne geneeskunder
Longziekten
Maag-, Darm- en Leverziekten
MDL
Medical Oncology
N/A
NA
Nefrologie
Nephrology
Neurology
NL10003: Internal medicine
Obstetrics & Gynecology
Oncologie
Oncology
Ophthalmology
Rheumatology
Surgery

Clinical trials at this site (122)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk sco… Pending

2024-512850-10-00 Resectable colorectal rectal metastases without extrahe 5
Ultrasound-guided Radiofrequency Ablation versus radioactive Iodine as treatment for Hyperthyroidism caused by Solitary Autonomous Thyroid N… Pending

2024-515602-34-01 Hyperactive thyroid nodules 11
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCL… Pending

2025-520792-67-00 Patients with advanced, metastatic NSCLC that have not 5
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of ve… Pending

2025-524283-38-00 Relapsed or refractory chronic lymphocytic leukemia 5
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Chronic Kidney Disease 4
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting

2024-511267-28-00 B-cell malignancies 5 2021-02-17
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Recruiting

2023-506194-35-00 Colorectal liver metastases 5 2026-05-22
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 treatment-naive Chronic Lymphocytic Leukemia 5 2026-04-29
A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2… Recruiting

2025-521936-12-00 Adults with Type 2 Diabetes and/or Metabolic Syndrome 5 2026-04-24
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac… Recruiting

2023-507801-32-00 Isolated Subsegmental Pulmonary Embolism 6 2026-04-22
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) Recruiting

2025-523283-21-00 Peripheral Arterial Disease 5 2026-02-17